Last reviewed · How we verify
Vitamin K 2
Vitamin K 2 is a Vitamin K analog Small molecule drug developed by Catholic University of Salta. It is currently FDA-approved for Bone health and osteoporosis prevention, Cardiovascular health and vascular calcification prevention. Also known as: PLACEBO GROUP, menaquinone-7.
Vitamin K2 acts as a cofactor for gamma-carboxylation of bone and vascular proteins, enabling their biological activity in bone mineralization and cardiovascular health.
Vitamin K2 is a small molecule that has been studied as a potential treatment for various conditions related to calcification of heart valves, including aortic valve stenosis and mitral valve calcification. It works through the carboxylation mechanism of matrix Gla protein (MGP), which is involved in inhibiting calcification.
At a glance
| Generic name | Vitamin K 2 |
|---|---|
| Also known as | PLACEBO GROUP, menaquinone-7 |
| Sponsor | Catholic University of Salta |
| Drug class | Vitamin K analog |
| Target | Gamma-glutamyl carboxylase cofactor |
| Modality | Small molecule |
| Therapeutic area | Bone health, Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Vitamin K2 (menaquinone) is an essential cofactor for the enzyme gamma-glutamyl carboxylase, which catalyzes the post-translational carboxylation of glutamic acid residues in bone proteins (osteocalcin, matrix Gla protein) and vascular proteins. This carboxylation is required for these proteins to bind calcium and exert their physiological effects on bone metabolism and vascular calcification prevention.
Approved indications
- Bone health and osteoporosis prevention
- Cardiovascular health and vascular calcification prevention
Common side effects
- Gastrointestinal upset
- Hypersensitivity reactions
Key clinical trials
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- SWITCH: Apixaban vs Vitamin K in HM3 (PHASE3)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- Ischemic Stroke Nutrition Intervention Study (NA)
- Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device (PHASE4)
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin K 2 CI brief — competitive landscape report
- Vitamin K 2 updates RSS · CI watch RSS
- Catholic University of Salta portfolio CI
Frequently asked questions about Vitamin K 2
What is Vitamin K 2?
How does Vitamin K 2 work?
What is Vitamin K 2 used for?
Who makes Vitamin K 2?
Is Vitamin K 2 also known as anything else?
What drug class is Vitamin K 2 in?
What development phase is Vitamin K 2 in?
What are the side effects of Vitamin K 2?
What does Vitamin K 2 target?
Related
- Drug class: All Vitamin K analog drugs
- Target: All drugs targeting Gamma-glutamyl carboxylase cofactor
- Manufacturer: Catholic University of Salta — full pipeline
- Therapeutic area: All drugs in Bone health, Cardiovascular
- Indication: Drugs for Bone health and osteoporosis prevention
- Indication: Drugs for Cardiovascular health and vascular calcification prevention
- Also known as: PLACEBO GROUP, menaquinone-7
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing